View Older Stories View More Recent Stories
-
Streetinsider.com's Hot Lunchtime Reads 04/07: (KR) (MSFT) (SRPT) (MDVN)
-
Pre-Clinical Data for MEI Pharma's (MEIP) Pracinostat Will Set Development Tone - Roth Capital
-
American Apparel (APP) Price Target Reduced to $0.75 at Roth
-
Roth Affirms Hydrogenics (HYGS) at 'Bur'; Customer-Driven Hiccup Doesn't Affect Overall Thesis
-
Ocean Power Technologies (OPTT) Prices 3.8M Offering at $3.10/sh
-
Ocean Power Technologies Prices Underwritten Public Offering of Common Stock
-
Roth Capital Starts Energy Fuels (UUUU) at Buy
-
Roth Capital Starts Uranium Resources (URRE) at Buy
-
Ocean Power Technologies, Inc. (OPTT) Plans Common Stock Offering
-
Ocean Power Technologies Announces Proposed Public Offering of Common Stock
-
SolarCity (SCTY) ABS Offerings are Evolutionary Step Toward Lower-Cost Financing - Roth
-
AGTC Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Catyalyst Pharma (CPRX) Prices 11.33M Common Offering at $2.21/Share
-
Endocyte (ECYT) Closes 5.18M Offering; Sees Net Proceeds of $101.8M
-
Endocyte, Inc. Closes Public Offering of Common Stock
-
Roth Affirms Keryx (KERX) at 'Buy'; ESRD Overhang Removed
-
Roth Lifts PT on Stemline (STML) to $62; Sees 'Pivotal' Year in 2014
-
Roth Sees Regeneron/Sanofi Alirocumab Phase 2 Results as Positive; Maintains 'Buy' Rating (REGN)
-
Clean Diesel (CDTI) Announces $6.9M Equity Raise
-
CDTi to Raise Approximately $6.9 Million
-
Roth Capital Positive on Palatin (PTN) Granting Bremelanotide Extension
-
Roth Raises PT on Regeneron (REGN) to $382; ODYSSEY MONO, Alirocumab Data Bolsters Positive Outlook
-
Regeneron Pharma (REGN) PT Raised to $382 at Roth Capital
-
Roth Boosts PT on Curis (CRIS) to $10; '427 Overhang Now Lifted
-
Notable 52-Week Highs and Lows of the Day 03/28: (AA) (ELY) (INVN) High; (EXEL) (SPEX) Low
-
Notable Analyst Rating Changes 03/28: (SCTY) (CTSH) (INVN) Upgraded; (PNW) (CIEN) (PCG) Downgraded
-
Cytokinetics (CYTK) Starts COSMIC-HF Phase II Enrollment; BENEFIT-ALS Still in Focus - Roth
-
Endocyte (ECYT) Prices 4.5M Share Offering at $21
-
Roth Capital Upgrades InvenSense (INVN) to Buy
-
Endocyte, Inc. Prices Public Offering of Common Stock
-
Cytokinetics' (CYTK) Initiation of CK-2127107 Phase I is Positive Development - Roth
-
Applied Genetic Technologies (AGTC) IPO Opens Higher
-
Alt-Energy Names Show Early Gains (FCEL)(BLDP) (PLUG)
-
Roth Starts Active Power (ACPW) at Buy; Refocused Company Should See N-T Gains
-
Applied Genetic Technologies (AGTC) IPO Prices at $12, Below Range
-
Roth Capital Starts Active Power (ACPW) at Buy
-
AGTC Announces Pricing of Initial Public Offering
-
RGS Energy's (RGSE) New Financing Strategy Could Provide Upside; Roth Boosts PT to $6
-
American Apparel (APP) Prices 61M Common Offering at 50c/Share
-
Notable Analyst Rating Changes 03/25: (SOL) (RAX) (PCAR) Upgraded; (HIMX) (PHM) (ACI) Downgraded
-
Pre-Open Stock Movers 3/25: (GALT) (ECYT) (RAX) Higher; (IDN) (HIMX) (GIII) Lower (more...)
-
Roth Upgrades ReneSola (SOL) to Buy; Sees Outperformance Continuing on Strong Differentiation
-
American Apparel (APP) Commences $30.5M Cmmon Stock Offering
-
Roth Capital Upgrades Silvercrest Mines (SVLC) to Buy
-
Roth Capital Upgrades ReneSola Ltd. (SOL) to Buy
-
Stronger-than-Expected FY13 Results Set Rexahn Pharma (RNN) Up for Promising FY14 - Analyst
-
Roth Cuts PT on Curis (CRIS) to $9; Erivedge Phase 2 Misses Roche's (RHHBY) Internal Expectations
-
Palatin Technologies (PTN) is Ready to Soar; Roth Reaffirms 'Buy' Rating
-
Synta Pharma (SNTA) Positive Trajectory Reinforced by Latest ENCHANT-1 Data - Roth
-
Roth on Sidelines with Yingli Green Energy (YGE); Leverage Will Continue to Limit Upside

